Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Mar 06, 2024 6:11pm
233 Views
Post# 35919250

Time to get back to reality.

Time to get back to reality.

First a claim was made that Matt said his company shares were overvalued.
That is 100% lie. As such I'll be reporting that information to Onc I.R. To instigate liablous litigation.
Going on with your convoluted " evidence" is a lot of conjecture.
Beyond a possible blackout, it is quite possible they were/ are in negotiations, preventing an insider trade such as that.
All we know for sure, the options were available. 
Assuming Matt did or did not exercise the options, is based on plenty of information we know nothing about.
Why he did & did not report  ? Or did not? Exercise. 

Neither of which validates your statement that Matt said the sp was overvalued.
Everyone on here, myself included uses creative freedom with their statements.
However stating that Matt said/ indicated or implied that the SP is/ was overvalued is a 100% lie.
Onc has had its share of bad timing the last few months.
As a shareholder, I take extream exception to people out & out lying , especially when it implies a direct. Quote of the CEO.
Funny, the same FUDsters work real hard to discredit Onc mangement as missleading etc, All the while doing exactly that them selves.
Have a good day all

 

<< Previous
Bullboard Posts
Next >>